Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Company Deals

Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub

Fineline Cube Jul 24, 2026
Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026
Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

Lilly’s Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market

Fineline Cube Jul 24, 2026
Company Drug

Aidea Pharma Secures NMPA Approval for Darunavir, Challenging J&J’s Prezista in China’s HIV Treatment Market

Fineline Cube Jul 24, 2026
Company Deals

Simnova Secures RMB 200 Million in Series A+ Funding to Advance CAR Therapy Pipeline

Fineline Cube Mar 11, 2024

Simnova, a Shenzhen-based developer of chimeric antigen receptor (CAR) adoptive cell therapies, has successfully raised...

Company Drug

ClouDr Launches Dapagliflozin, Generic Version of AstraZeneca’s Forxiga, After NMPA Approval

Fineline Cube Mar 11, 2024

Hangzhou Kang Ming Information Technology Co., Ltd. (HKG: 9955), known as “ClouDr,” has officially launched...

Company Drug Legal / IP

BeiGene Launches Legal Action Against Sandoz and MSN Over Brukinsa Patent Infringement

Fineline Cube Mar 11, 2024

BeiGene Ltd. (NASDAQ: BGNE; HKG: 6160; SHA: 688235), the China-based biotech firm, has initiated patent...

Company Drug

Eli Lilly Delays Donanemab Action Date as FDA Calls for Advisory Committee Review

Fineline Cube Mar 11, 2024

Eli Lilly (NYSE: LLY) has announced a delay in the action date for its Alzheimer’s...

Policy / Regulatory

China Cracks Down on Medical Insurance Fraud with New Guidelines and Increased Prosecutions

Fineline Cube Mar 11, 2024

China’s Supreme People’s Court, along with the Supreme People’s Procuratorate and the Ministry of Public...

Company Drug

FDA Approves Wegovy for Cardiovascular Risk Reduction in Obese Patients, First of Its Kind

Fineline Cube Mar 11, 2024

The U.S. Food and Drug Administration (FDA) granted an indication extension approval last week to...

Company Drug

Amgen Reports Positive Results for Otezla in Pediatric Psoriasis Trial

Fineline Cube Mar 11, 2024

Amgen (NASDAQ: AMGN) provided an update last week on a late-stage trial evaluating its PDE4...

Company

Merck’s 2023 Annual Report: A Mixed Bag Amid Global Challenges

Fineline Cube Mar 8, 2024

Merck KGaA (ETR: MRK), a leading German chemical, reported a 5.6% decline in its global...

Company

GSK Reports US Adult Non-Flu Vaccination Rates Recover Post-Pandemic

Fineline Cube Mar 8, 2024

GlaxoSmithKline (GSK; NYSE: GSK), a leading pharmaceutical company based in the UK, has reported that...

Company Drug

BMS’s Opdivo Secures FDA Approval for First-Line Urothelial Carcinoma Treatment

Fineline Cube Mar 8, 2024

The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS; NYSE: BMY)...

Company Drug

BeiGene’s Brukinsa Receives FDA Approval for Relapsed or Refractory Follicular Lymphoma

Fineline Cube Mar 8, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biotech company based in China,...

Company Drug

Visen Pharmaceuticals’ TransCon hGH Accepted for Review by China’s NMPA

Fineline Cube Mar 8, 2024

Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma and Chinese healthcare-focused investment firm Vivo...

Company Deals

Shandong Luoxin Pharmaceutical Partners with Xbiome to Access Microbiome Transplantation Technology

Fineline Cube Mar 8, 2024

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a pharmaceutical company based in China,...

Company Drug

Shanghai Fosun Pharma Gets NMPA Green Light for Universal NK Cell Therapy GCK-01 Clinical Study

Fineline Cube Mar 8, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company Drug

Novo Nordisk’s Anti-Obesity Drug Wegovy Eyed for China Launch in 2024

Fineline Cube Mar 8, 2024

Novo Nordisk (NYSE: NVO), a leading diabetes company based in Denmark, has reportedly informed investors...

Company Drug

China Grand Pharmaceutical Receives FDA Approval for Post-Surgical Ophthalmic Drug GPN00833

Fineline Cube Mar 8, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced that it has...

Company Drug

Shanghai Fosun Pharma Gets NMPA Green Light for XS-02 Solid Tumor Clinical Study

Fineline Cube Mar 8, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company Deals

Everest Medicines to Establish Integrated Kidney Disease Diagnosis and Treatment Ecosystem

Fineline Cube Mar 7, 2024

Everest Medicines (HKG: 1952), a Chinese pharmaceutical company, is set to collaborate with partners to...

Company Drug

Boehringer Ingelheim’s Spevigo Receives NMPA Approval for GPP Treatment in China

Fineline Cube Mar 7, 2024

German pharmaceutical giant Boehringer Ingelheim (BI) has announced that it has received marketing approval from...

Company Deals

Zylox-Tonbridge Medical Technology Secures Licensing Deal with Avinger to Boost Device Portfolio

Fineline Cube Mar 7, 2024

Zylox-Tonbridge Medical Technology (HKG: 2190), a China-based developer of nerve and peripheral vascular interventional devices,...

Posts pagination

1 … 425 426 427 … 699

Recent updates

  • Lilly’s Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market
  • Aidea Pharma Secures NMPA Approval for Darunavir, Challenging J&J’s Prezista in China’s HIV Treatment Market
  • Harbour BioMed Issues Profit Alert: H1 Revenue Expected at $120-125M on Strong Platform Licensing Growth
  • Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed/Refractory DLBCL
  • Hengrui Pharmaceuticals Secures NMPA First-Line Approval for Camrelizumab-Famitinib Combo in PD-L1-Positive Cervical Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Lilly’s Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market

Company Drug

Aidea Pharma Secures NMPA Approval for Darunavir, Challenging J&J’s Prezista in China’s HIV Treatment Market

Company

Harbour BioMed Issues Profit Alert: H1 Revenue Expected at $120-125M on Strong Platform Licensing Growth

Company Drug

Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed/Refractory DLBCL

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.